Home > > Global Gene Therapy Market Report
TABLE OF CONTENTS CHAPTER 1: RESEARCH METHODOLOGY 1.1. Delivery Model 1.2. Hypothesis Creation 1.3. Revenue narrow down of Companies and in-depth interviews 1.4. Data Triangulation and Validation 1.5. About Us 1.6. Key market segments CHAPTER 2: PREMIUM INSIGHTS CHAPTER 3: GLOBAL GENE THERAPY MARKET, BY VECTOR 3.1. OVERVIEW 3.2. NON-VIRAL VECTORS 3.2.1. NON-VIRAL VECTORS MARKET, BY REGION 3.2.1.1. NORTH AMERICA NON-VIRAL VECTORS MARKET, BY COUNTRY 3.2.1.2. EUROPE NON-VIRAL VECTORS MARKET, BY COUNTRY 3.2.1.3. ASIA NON-VIRAL VECTORS MARKET, BY COUNTRY 3.2.1.4. MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET, BY COUNTRY 3.3. VIRAL VECTORS 3.3.1. VIRAL VECTORS MARKET, BY REGION 3.3.1.1. NORTH AMERICA VIRAL VECTORS MARKET, BY COUNTRY 3.3.1.2. EUROPE VIRAL VECTORS MARKET, BY COUNTRY 3.3.1.3. ASIA VIRAL VECTORS MARKET, BY COUNTRY 3.3.1.4. MIDDLE EAST & AFRICA VIRAL VECTORS MARKET, BY COUNTRY CHAPTER 4: GLOBAL GENE THERAPY MARKET, BY INDICATION 4.1. OVERVIEW 4.2. NEUROLOGICAL DISEASES 4.2.1. NEUROLOGICAL DISEASES MARKET, BY REGION 4.2.1.1. NORTH AMERICA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 4.2.1.2. EUROPE NEUROLOGICAL DISEASES MARKET, BY COUNTRY 4.2.1.3. ASIA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 4.2.1.4. MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 4.3. CANCER 4.3.1. CANCER MARKET, BY REGION 4.3.1.1. NORTH AMERICA CANCER MARKET, BY COUNTRY 4.3.1.2. EUROPE CANCER MARKET, BY COUNTRY 4.3.1.3. ASIA CANCER MARKET, BY COUNTRY 4.3.1.4. MIDDLE EAST & AFRICA CANCER MARKET, BY COUNTRY 4.4. HEPATOLOGICAL DISEASES 4.4.1. HEPATOLOGICAL DISEASES MARKET, BY REGION 4.4.1.1. NORTH AMERICA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 4.4.1.2. EUROPE HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 4.4.1.3. ASIA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 4.4.1.4. MIDDLE EAST & AFRICA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 4.5. DUCHENNE MUSCULAR DYSTROPHY 4.5.1. DUCHENNE MUSCULAR DYSTROPHY MARKET, BY REGION 4.5.1.1. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 4.5.1.2. EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 4.5.1.3. ASIA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 4.5.1.4. MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 4.6. OTHER INDICATIONS 4.6.1. OTHER INDICATIONS MARKET, BY REGION 4.6.1.1. NORTH AMERICA OTHER INDICATIONS MARKET, BY COUNTRY 4.6.1.2. EUROPE OTHER INDICATIONS MARKET, BY COUNTRY 4.6.1.3. ASIA OTHER INDICATIONS MARKET, BY COUNTRY 4.6.1.4. MIDDLE EAST & AFRICA OTHER INDICATIONS MARKET, BY COUNTRY CHAPTER 5: GLOBAL GENE THERAPY MARKET, BY DELIVERY METHOD 5.1. OVERVIEW 5.2. IN-VIVO GENE THERAOY 5.2.1. IN-VIVO GENE THERAOY MARKET, BY REGION 5.2.1.1. NORTH AMERICA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 5.2.1.2. EUROPE IN-VIVO GENE THERAOY MARKET, BY COUNTRY 5.2.1.3. ASIA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 5.2.1.4. MIDDLE EAST & AFRICA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 5.3. EX-VIVO GENE THERAOY 5.3.1. EX-VIVO GENE THERAOY MARKET, BY REGION 5.3.1.1. NORTH AMERICA EX-VIVO GENE THERAOY MARKET, BY COUNTRY 5.3.1.2. EUROPE EX-VIVO GENE THERAOY MARKET, BY COUNTRY 5.3.1.3. ASIA EX-VIVO GENE THERAOY MARKET, BY COUNTRY 5.3.1.4. MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET, BY COUNTRY CHAPTER 6: GLOBAL GENE THERAPY MARKET, BY REGION 6.1. OVERVIEW 6.2. NORTH AMERICA 6.2.1. NORTH AMERICA GENE THERAPY MARKET, BY VECTOR 6.2.2. NORTH AMERICA GENE THERAPY MARKET, BY INDICATION 6.2.3. NORTH AMERICA GENE THERAPY MARKET, BY DELIVERY METHOD 6.2.4. NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY 6.2.4.1. U.S. 6.2.4.1.1. U.S. GENE THERAPY MARKET, BY VECTOR 6.2.4.1.2. U.S. GENE THERAPY MARKET, BY INDICATION 6.2.4.1.3. U.S. GENE THERAPY MARKET, BY DELIVERY METHOD 6.2.4.2. CANADA 6.2.4.2.1. CANADA GENE THERAPY MARKET, BY VECTOR 6.2.4.2.2. CANADA GENE THERAPY MARKET, BY INDICATION 6.2.4.2.3. CANADA GENE THERAPY MARKET, BY DELIVERY METHOD 6.3. EUROPE 6.3.1. EUROPE GENE THERAPY MARKET, BY VECTOR 6.3.2. EUROPE GENE THERAPY MARKET, BY INDICATION 6.3.3. EUROPE GENE THERAPY MARKET, BY DELIVERY METHOD 6.3.4. EUROPE GENE THERAPY MARKET, BY COUNTRY 6.3.4.1. GERMANY 6.3.4.1.1. GERMANY GENE THERAPY MARKET, BY VECTOR 6.3.4.1.2. GERMANY GENE THERAPY MARKET, BY INDICATION 6.3.4.1.3. GERMANY GENE THERAPY MARKET, BY DELIVERY METHOD 6.3.4.2. FRANCE 6.3.4.2.1. FRANCE GENE THERAPY MARKET, BY VECTOR 6.3.4.2.2. FRANCE GENE THERAPY MARKET, BY INDICATION 6.3.4.2.3. FRANCE GENE THERAPY MARKET, BY DELIVERY METHOD 6.3.4.3. U.K. 6.3.4.3.1. U.K. GENE THERAPY MARKET, BY VECTOR 6.3.4.3.2. U.K. GENE THERAPY MARKET, BY INDICATION 6.3.4.3.3. U.K. GENE THERAPY MARKET, BY DELIVERY METHOD 6.3.4.4. ITALY 6.3.4.4.1. ITALY GENE THERAPY MARKET, BY VECTOR 6.3.4.4.2. ITALY GENE THERAPY MARKET, BY INDICATION 6.3.4.4.3. ITALY GENE THERAPY MARKET, BY DELIVERY METHOD 6.3.4.5. SPAIN 6.3.4.5.1. SPAIN GENE THERAPY MARKET, BY VECTOR 6.3.4.5.2. SPAIN GENE THERAPY MARKET, BY INDICATION 6.3.4.5.3. SPAIN GENE THERAPY MARKET, BY DELIVERY METHOD 6.3.4.6. ROE 6.3.4.6.1. ROE GENE THERAPY MARKET, BY VECTOR 6.3.4.6.2. ROE GENE THERAPY MARKET, BY INDICATION 6.3.4.6.3. ROE GENE THERAPY MARKET, BY DELIVERY METHOD 6.4. ASIA 6.4.1. ASIA GENE THERAPY MARKET, BY VECTOR 6.4.2. ASIA GENE THERAPY MARKET, BY INDICATION 6.4.3. ASIA GENE THERAPY MARKET, BY DELIVERY METHOD 6.4.4. ASIA GENE THERAPY MARKET, BY COUNTRY 6.4.4.1. JAPAN 6.4.4.1.1. JAPAN GENE THERAPY MARKET, BY VECTOR 6.4.4.1.2. JAPAN GENE THERAPY MARKET, BY INDICATION 6.4.4.1.3. JAPAN GENE THERAPY MARKET, BY DELIVERY METHOD 6.4.4.2. CHINA 6.4.4.2.1. CHINA GENE THERAPY MARKET, BY VECTOR 6.4.4.2.2. CHINA GENE THERAPY MARKET, BY INDICATION 6.4.4.2.3. CHINA GENE THERAPY MARKET, BY DELIVERY METHOD 6.4.4.3. ROAPAC 6.4.4.3.1. ROAPAC GENE THERAPY MARKET, BY VECTOR 6.4.4.3.2. ROAPAC GENE THERAPY MARKET, BY INDICATION 6.4.4.3.3. ROAPAC GENE THERAPY MARKET, BY DELIVERY METHOD 6.5. MIDDLE EAST & AFRICA 6.5.1. MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY VECTOR 6.5.2. MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY INDICATION 6.5.3. MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY DELIVERY METHOD 6.5.4. MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY COUNTRY 6.5.4.1. LATIN AMERICA 6.5.4.1.1. LATIN AMERICA GENE THERAPY MARKET, BY VECTOR 6.5.4.1.2. LATIN AMERICA GENE THERAPY MARKET, BY INDICATION 6.5.4.1.3. LATIN AMERICA GENE THERAPY MARKET, BY DELIVERY METHOD 6.5.4.2. MEA 6.5.4.2.1. MEA GENE THERAPY MARKET, BY VECTOR 6.5.4.2.2. MEA GENE THERAPY MARKET, BY INDICATION 6.5.4.2.3. MEA GENE THERAPY MARKET, BY DELIVERY METHOD TABLE 108. MEA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION)LIST OF TABLES TABLE 01. GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 02. GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 03. GLOBAL GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 04. GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 05. GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 06. NON-VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 07. NORTH AMERICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 08. EUROPE NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 09. ASIA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 10. MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 11. VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 12. NORTH AMERICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 13. EUROPE VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 14. ASIA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 15. MIDDLE EAST & AFRICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 16. GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 17. NEUROLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 18. NORTH AMERICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 19. EUROPE NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 20. ASIA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 21. MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 22. CANCER MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 23. NORTH AMERICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 24. EUROPE CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 25. ASIA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 26. MIDDLE EAST & AFRICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 27. HEPATOLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 28. NORTH AMERICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 29. EUROPE HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 30. ASIA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 31. MIDDLE EAST & AFRICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 32. DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 33. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 34. EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 35. ASIA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 36. MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 37. OTHER INDICATIONS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 38. NORTH AMERICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 39. EUROPE OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 40. ASIA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 41. MIDDLE EAST & AFRICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 42. GLOBAL GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 43. IN-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 44. NORTH AMERICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 45. EUROPE IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 46. ASIA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 47. MIDDLE EAST & AFRICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 48. EX-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 49. NORTH AMERICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 50. EUROPE EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 51. ASIA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 52. MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 53. GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 54. NORTH AMERICA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) TABLE 55. NORTH AMERICA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) TABLE 56. NORTH AMERICA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) TABLE 57. NORTH AMERICA GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 58. U.S. GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 59. U.S. GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 60. U.S. GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 61. CANADA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 62. CANADA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 63. CANADA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 64. EUROPE GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) TABLE 65. EUROPE GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) TABLE 66. EUROPE GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) TABLE 67. EUROPE GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 68. GERMANY GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 69. GERMANY GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 70. GERMANY GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 71. FRANCE GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 72. FRANCE GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 73. FRANCE GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 74. U.K. GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 75. U.K. GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 76. U.K. GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 77. ITALY GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 78. ITALY GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 79. ITALY GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 80. SPAIN GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 81. SPAIN GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 82. SPAIN GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 83. ROE GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 84. ROE GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 85. ROE GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 86. ASIA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) TABLE 87. ASIA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) TABLE 88. ASIA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) TABLE 89. ASIA GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 90. JAPAN GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 91. JAPAN GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 92. JAPAN GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 93. CHINA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 94. CHINA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 95. CHINA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 96. ROAPAC GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 97. ROAPAC GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 98. ROAPAC GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 99. MIDDLE EAST & AFRICA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) TABLE 100. MIDDLE EAST & AFRICA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) TABLE 101. MIDDLE EAST & AFRICA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) TABLE 102. MIDDLE EAST & AFRICA GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 103. LATIN AMERICA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 104. LATIN AMERICA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 105. LATIN AMERICA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 106. MEA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 107. MEA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 108. MEA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION)LIST OF FIGURES CHAPTER 1: RESEARCH METHODOLOGY 1.1. Delivery Model 1.2. Hypothesis Creation 1.3. Revenue narrow down of Companies and in-depth interviews 1.4. Data Triangulation and Validation 1.5. About Us 1.6. Key market segments CHAPTER 2: PREMIUM INSIGHTS CHAPTER 3: GLOBAL GENE THERAPY MARKET, BY VECTOR 3.1. OVERVIEW 3.2. NON-VIRAL VECTORS 3.2.1. NON-VIRAL VECTORS MARKET, BY REGION 3.2.1.1. NORTH AMERICA NON-VIRAL VECTORS MARKET, BY COUNTRY 3.2.1.2. EUROPE NON-VIRAL VECTORS MARKET, BY COUNTRY 3.2.1.3. ASIA NON-VIRAL VECTORS MARKET, BY COUNTRY 3.2.1.4. MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET, BY COUNTRY 3.3. VIRAL VECTORS 3.3.1. VIRAL VECTORS MARKET, BY REGION 3.3.1.1. NORTH AMERICA VIRAL VECTORS MARKET, BY COUNTRY 3.3.1.2. EUROPE VIRAL VECTORS MARKET, BY COUNTRY 3.3.1.3. ASIA VIRAL VECTORS MARKET, BY COUNTRY 3.3.1.4. MIDDLE EAST & AFRICA VIRAL VECTORS MARKET, BY COUNTRY CHAPTER 4: GLOBAL GENE THERAPY MARKET, BY INDICATION 4.1. OVERVIEW 4.2. NEUROLOGICAL DISEASES 4.2.1. NEUROLOGICAL DISEASES MARKET, BY REGION 4.2.1.1. NORTH AMERICA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 4.2.1.2. EUROPE NEUROLOGICAL DISEASES MARKET, BY COUNTRY 4.2.1.3. ASIA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 4.2.1.4. MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 4.3. CANCER 4.3.1. CANCER MARKET, BY REGION 4.3.1.1. NORTH AMERICA CANCER MARKET, BY COUNTRY 4.3.1.2. EUROPE CANCER MARKET, BY COUNTRY 4.3.1.3. ASIA CANCER MARKET, BY COUNTRY 4.3.1.4. MIDDLE EAST & AFRICA CANCER MARKET, BY COUNTRY 4.4. HEPATOLOGICAL DISEASES 4.4.1. HEPATOLOGICAL DISEASES MARKET, BY REGION 4.4.1.1. NORTH AMERICA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 4.4.1.2. EUROPE HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 4.4.1.3. ASIA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 4.4.1.4. MIDDLE EAST & AFRICA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 4.5. DUCHENNE MUSCULAR DYSTROPHY 4.5.1. DUCHENNE MUSCULAR DYSTROPHY MARKET, BY REGION 4.5.1.1. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 4.5.1.2. EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 4.5.1.3. ASIA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 4.5.1.4. MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 4.6. OTHER INDICATIONS 4.6.1. OTHER INDICATIONS MARKET, BY REGION 4.6.1.1. NORTH AMERICA OTHER INDICATIONS MARKET, BY COUNTRY 4.6.1.2. EUROPE OTHER INDICATIONS MARKET, BY COUNTRY 4.6.1.3. ASIA OTHER INDICATIONS MARKET, BY COUNTRY 4.6.1.4. MIDDLE EAST & AFRICA OTHER INDICATIONS MARKET, BY COUNTRY CHAPTER 5: GLOBAL GENE THERAPY MARKET, BY DELIVERY METHOD 5.1. OVERVIEW 5.2. IN-VIVO GENE THERAOY 5.2.1. IN-VIVO GENE THERAOY MARKET, BY REGION 5.2.1.1. NORTH AMERICA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 5.2.1.2. EUROPE IN-VIVO GENE THERAOY MARKET, BY COUNTRY 5.2.1.3. ASIA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 5.2.1.4. MIDDLE EAST & AFRICA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 5.3. EX-VIVO GENE THERAOY 5.3.1. EX-VIVO GENE THERAOY MARKET, BY REGION 5.3.1.1. NORTH AMERICA EX-VIVO GENE THERAOY MARKET, BY COUNTRY 5.3.1.2. EUROPE EX-VIVO GENE THERAOY MARKET, BY COUNTRY 5.3.1.3. ASIA EX-VIVO GENE THERAOY MARKET, BY COUNTRY 5.3.1.4. MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET, BY COUNTRY CHAPTER 6: GLOBAL GENE THERAPY MARKET, BY REGION 6.1. OVERVIEW 6.2. NORTH AMERICA 6.2.1. NORTH AMERICA GENE THERAPY MARKET, BY VECTOR 6.2.2. NORTH AMERICA GENE THERAPY MARKET, BY INDICATION 6.2.3. NORTH AMERICA GENE THERAPY MARKET, BY DELIVERY METHOD 6.2.4. NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY 6.2.4.1. U.S. 6.2.4.1.1. U.S. GENE THERAPY MARKET, BY VECTOR 6.2.4.1.2. U.S. GENE THERAPY MARKET, BY INDICATION 6.2.4.1.3. U.S. GENE THERAPY MARKET, BY DELIVERY METHOD 6.2.4.2. CANADA 6.2.4.2.1. CANADA GENE THERAPY MARKET, BY VECTOR 6.2.4.2.2. CANADA GENE THERAPY MARKET, BY INDICATION 6.2.4.2.3. CANADA GENE THERAPY MARKET, BY DELIVERY METHOD 6.3. EUROPE 6.3.1. EUROPE GENE THERAPY MARKET, BY VECTOR 6.3.2. EUROPE GENE THERAPY MARKET, BY INDICATION 6.3.3. EUROPE GENE THERAPY MARKET, BY DELIVERY METHOD 6.3.4. EUROPE GENE THERAPY MARKET, BY COUNTRY 6.3.4.1. GERMANY 6.3.4.1.1. GERMANY GENE THERAPY MARKET, BY VECTOR 6.3.4.1.2. GERMANY GENE THERAPY MARKET, BY INDICATION 6.3.4.1.3. GERMANY GENE THERAPY MARKET, BY DELIVERY METHOD 6.3.4.2. FRANCE 6.3.4.2.1. FRANCE GENE THERAPY MARKET, BY VECTOR 6.3.4.2.2. FRANCE GENE THERAPY MARKET, BY INDICATION 6.3.4.2.3. FRANCE GENE THERAPY MARKET, BY DELIVERY METHOD 6.3.4.3. U.K. 6.3.4.3.1. U.K. GENE THERAPY MARKET, BY VECTOR 6.3.4.3.2. U.K. GENE THERAPY MARKET, BY INDICATION 6.3.4.3.3. U.K. GENE THERAPY MARKET, BY DELIVERY METHOD 6.3.4.4. ITALY 6.3.4.4.1. ITALY GENE THERAPY MARKET, BY VECTOR 6.3.4.4.2. ITALY GENE THERAPY MARKET, BY INDICATION 6.3.4.4.3. ITALY GENE THERAPY MARKET, BY DELIVERY METHOD 6.3.4.5. SPAIN 6.3.4.5.1. SPAIN GENE THERAPY MARKET, BY VECTOR 6.3.4.5.2. SPAIN GENE THERAPY MARKET, BY INDICATION 6.3.4.5.3. SPAIN GENE THERAPY MARKET, BY DELIVERY METHOD 6.3.4.6. ROE 6.3.4.6.1. ROE GENE THERAPY MARKET, BY VECTOR 6.3.4.6.2. ROE GENE THERAPY MARKET, BY INDICATION 6.3.4.6.3. ROE GENE THERAPY MARKET, BY DELIVERY METHOD 6.4. ASIA 6.4.1. ASIA GENE THERAPY MARKET, BY VECTOR 6.4.2. ASIA GENE THERAPY MARKET, BY INDICATION 6.4.3. ASIA GENE THERAPY MARKET, BY DELIVERY METHOD 6.4.4. ASIA GENE THERAPY MARKET, BY COUNTRY 6.4.4.1. JAPAN 6.4.4.1.1. JAPAN GENE THERAPY MARKET, BY VECTOR 6.4.4.1.2. JAPAN GENE THERAPY MARKET, BY INDICATION 6.4.4.1.3. JAPAN GENE THERAPY MARKET, BY DELIVERY METHOD 6.4.4.2. CHINA 6.4.4.2.1. CHINA GENE THERAPY MARKET, BY VECTOR 6.4.4.2.2. CHINA GENE THERAPY MARKET, BY INDICATION 6.4.4.2.3. CHINA GENE THERAPY MARKET, BY DELIVERY METHOD 6.4.4.3. ROAPAC 6.4.4.3.1. ROAPAC GENE THERAPY MARKET, BY VECTOR 6.4.4.3.2. ROAPAC GENE THERAPY MARKET, BY INDICATION 6.4.4.3.3. ROAPAC GENE THERAPY MARKET, BY DELIVERY METHOD 6.5. MIDDLE EAST & AFRICA 6.5.1. MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY VECTOR 6.5.2. MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY INDICATION 6.5.3. MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY DELIVERY METHOD 6.5.4. MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY COUNTRY 6.5.4.1. LATIN AMERICA 6.5.4.1.1. LATIN AMERICA GENE THERAPY MARKET, BY VECTOR 6.5.4.1.2. LATIN AMERICA GENE THERAPY MARKET, BY INDICATION 6.5.4.1.3. LATIN AMERICA GENE THERAPY MARKET, BY DELIVERY METHOD 6.5.4.2. MEA 6.5.4.2.1. MEA GENE THERAPY MARKET, BY VECTOR 6.5.4.2.2. MEA GENE THERAPY MARKET, BY INDICATION 6.5.4.2.3. MEA GENE THERAPY MARKET, BY DELIVERY METHOD TABLE 01. GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 02. GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 03. GLOBAL GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 04. GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 05. GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 06. NON-VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 07. NORTH AMERICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 08. EUROPE NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 09. ASIA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 10. MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 11. VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 12. NORTH AMERICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 13. EUROPE VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 14. ASIA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 15. MIDDLE EAST & AFRICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 16. GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 17. NEUROLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 18. NORTH AMERICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 19. EUROPE NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 20. ASIA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 21. MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 22. CANCER MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 23. NORTH AMERICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 24. EUROPE CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 25. ASIA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 26. MIDDLE EAST & AFRICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 27. HEPATOLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 28. NORTH AMERICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 29. EUROPE HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 30. ASIA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 31. MIDDLE EAST & AFRICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 32. DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 33. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 34. EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 35. ASIA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 36. MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 37. OTHER INDICATIONS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 38. NORTH AMERICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 39. EUROPE OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 40. ASIA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 41. MIDDLE EAST & AFRICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 42. GLOBAL GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 43. IN-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 44. NORTH AMERICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 45. EUROPE IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 46. ASIA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 47. MIDDLE EAST & AFRICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 48. EX-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 49. NORTH AMERICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 50. EUROPE EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 51. ASIA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 52. MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 53. GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 54. NORTH AMERICA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) TABLE 55. NORTH AMERICA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) TABLE 56. NORTH AMERICA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) TABLE 57. NORTH AMERICA GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 58. U.S. GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 59. U.S. GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 60. U.S. GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 61. CANADA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 62. CANADA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 63. CANADA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 64. EUROPE GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) TABLE 65. EUROPE GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) TABLE 66. EUROPE GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) TABLE 67. EUROPE GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 68. GERMANY GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 69. GERMANY GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 70. GERMANY GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 71. FRANCE GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 72. FRANCE GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 73. FRANCE GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 74. U.K. GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 75. U.K. GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 76. U.K. GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 77. ITALY GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 78. ITALY GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 79. ITALY GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 80. SPAIN GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 81. SPAIN GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 82. SPAIN GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 83. ROE GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 84. ROE GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 85. ROE GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 86. ASIA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) TABLE 87. ASIA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) TABLE 88. ASIA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) TABLE 89. ASIA GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 90. JAPAN GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 91. JAPAN GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 92. JAPAN GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 93. CHINA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 94. CHINA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 95. CHINA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 96. ROAPAC GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 97. ROAPAC GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 98. ROAPAC GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 99. MIDDLE EAST & AFRICA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) TABLE 100. MIDDLE EAST & AFRICA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) TABLE 101. MIDDLE EAST & AFRICA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) TABLE 102. MIDDLE EAST & AFRICA GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 103. LATIN AMERICA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 104. LATIN AMERICA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 105. LATIN AMERICA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 106. MEA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 107. MEA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 108. MEA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION)